Oppenheimer Sticks to Their Buy Rating for K2M Group Holdings
Oppenheimer analyst Steven Lichtman maintained a Buy rating on K2M Group Holdings (NASDAQ: KTWO) today. The company’s shares opened today at $21.15.
According to TipRanks.com, Lichtman has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.1% and a 53.7% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Motus Gi Holdings Inc, Integra Lifesciences, and Wright Medical Group.
Currently, the analyst consensus on K2M Group Holdings is Strong Buy and the average price target is $25, representing a 18.2% upside.
In a report issued on May 31, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $28 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.99 and a one-year low of $16.44. Currently, K2M Group Holdings has an average volume of 214.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
K2M Group Holdings, Inc. is a global medical device company. It focused on designing, developing and commercializing innovative and proprietary complex spine technologies and techniques. The company’s complex spine products are used by spine surgeons to treat some of the most difficult and challenging spinal pathologies, such as deformity, trauma and tumor.